Skip to content
OpenCapital
Get started

TTRX TTRX Deferred revenue, net of current portion

Deferred revenue, net of current portion at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$225.1M+6.3%
PTH
Pelthos Therapeutics Inc.PTHS
——
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
——

Other financials

Income statement

See full
Operating income-$1.2M-224%
Net income-$971.0K-196%
EPS (diluted)-$0.03-200%

Balance sheet

See full
Cash & equivalents$11.2M+613%
Total debt$6.0M—
Total equity$6.1M+647%
Total assets$18.6M—

Cash flow

See full
Operating cash flow-$1.6M-448%

Valuation

See full
Market cap$217.45M-17.7%
Enterprise value$212.24M—

Returns & leverage

See full
Return on equity-118.8%—
Debt / equity1×—
Current ratio2.2×—

Where this comes from

Reported directly by TTRX in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: TTRX’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about TTRX's deferred revenue, net of current portion.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TTRX's deferred revenue, net of current portion?
TTRX (TTRX) reported deferred revenue, net of current portion of $1.44M in Q1 2026.